VanEck JP Morgan EM Local Currency Bond ETF vs Medtronic PLC — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.81 (market cap $4.93B), while Medtronic PLC trades at $87.92 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 22.8× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Medtronic PLC pays a 3.28% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Medtronic PLC for 63 Days on average.
| EMLC | MDT | |
|---|---|---|
Market Cap | $4.93B | $112.24B |
Volume | 2,843,860 | 105,663,236 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $105.35 |
52-Week Low | $24.53 | $73.75 |
Typical Hold Time | 38 Days | 63 Days |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.77, down 0.24% on the day and hitting a new 52-week low. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though emerging market bonds have shown relative outperformance in 2026. Recent dividends of $0.14 and $0.13 were declared for October and August 2026 respectively.
The outlook remains cautious as dollar strength and rising global bond yields create challenges for emerging market local currency debt. While diversification benefits exist, near-term performance depends on currency dynamics and Federal Reserve policy direction. Key risks include currency volatility and global interest rate movements affecting bond valuations.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →